Cas No. 1269232-95-2, 3-Bromo-5-chloro-2-fluoroaniline

Encorafenib, a potent BRAF inhibitor, has demonstrated remarkable efficacy in treating patients with advanced melanoma harboring BRAF mutations. Our meticulously crafted intermediates ensure a seamless manufacturing process, enabling the timely production and supply of this life-saving medication. Join forces with us to revolutionize cancer care, providing patients with renewed hope and improved outcomes. Together, let's pave the way for a brighter future with Encorafenib.